Abivax SA (ABVX) AI Stock Analysis

• Market Cap: €6.16B
• Dividend Yield: N/A
• Average Volume (3M): 99.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: N/A
• EPS Growth: 18.52%
• Country: FR
• Employees: 69
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.17
• Shares Outstanding: 77,828,920
• 10 Day Avg. Volume: 99,142
• 30 Day Avg. Volume: 99,970
• PEG Ratio: 0.13
• Price to Book (P/B): 10.50
• Price to Sales (P/S): 39.49
• P/FCF Ratio: -2.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €85.00
• Price Target Upside: 7.32% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 54 Neutral
• Price Target: €78.00 ▼(-1.52% Downside)

Abivax SA's stock score is primarily influenced by its strong technical indicators, suggesting positive market momentum. However, financial performance challenges, including high leverage and negative profitability, weigh down the overall score. The lack of earnings call data and corporate events means these factors do not contribute to the score.

Abivax SA Business Overview & Revenue Model

Company Description

ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.

How the Company Makes Money

Abivax generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. The company may receive milestone payments and royalties from its partners upon achieving specific developmental or commercial targets for its drug candidates. Additionally, funding through grants and public offerings can contribute to its financial resources. As a clinical-stage company, its current revenue streams are limited, and it relies on external funding and partnerships to support its research and development activities.

Abivax SA Financial Statement Overview

Summary

Abivax SA shows significant revenue growth but struggles with profitability, having negative net income and operating cash flow. The balance sheet is highly leveraged, though the company maintains a strong cash position which supports liquidity.

Income Statement

Abivax SA has shown significant revenue growth from 2023 to 2024, but remains unprofitable with negative EBIT and net income. The company's gross profit margin is favorable, indicating effective cost control relative to revenue. However, the negative net profit margin highlights ongoing challenges in achieving profitability.

Balance Sheet

The financial structure of Abivax SA is marked by a relatively high debt-to-equity ratio, indicating significant leverage which could pose risks. The equity ratio is low, reflecting limited shareholder equity relative to total assets. However, the company maintains a strong cash position, supporting liquidity.

Cash Flow

Abivax SA's cash flow from operations is negative, pointing to challenges in generating cash from its core activities. Free cash flow is also negative, but the company has maintained its liquidity through financing activities. The operating cash flow to net income ratio is unfavorable, indicating reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.02M	10.79M	4.62M	4.58M	37.00K	14.00K
Gross Profit	6.02M	10.79M	4.49M	4.51M	-119.00K	-52.00K
EBITDA	-185.44M	-167.68M	-133.21M	-53.31M	-42.20M	-37.74M
Net Income	-195.39M	-176.24M	-147.74M	-60.74M	-42.45M	-37.55M
Balance Sheet
Total Assets	119.64M	205.23M	327.06M	73.35M	110.36M	71.30M
Cash, Cash Equivalents and Short-Term Investments	60.95M	144.22M	260.99M	26.95M	60.70M	29.30M
Total Debt	98.71M	97.36M	55.46M	39.16M	53.45M	33.98M
Total Liabilities	167.92M	164.64M	131.05M	71.47M	81.59M	66.63M
Stockholders Equity	-48.28M	40.58M	196.01M	7.19M	25.93M	17.90M
Cash Flow
Free Cash Flow	-137.42M	-154.72M	-97.39M	-69.55M	-47.30M	-30.72M
Operating Cash Flow	-136.96M	-154.07M	-97.13M	-65.58M	-45.66M	-29.82M
Investing Cash Flow	274.00K	15.76M	-8.10M	-3.73M	-1.46M	-575.00K
Financing Cash Flow	-23.98M	28.21M	335.29M	32.21M	82.68M	49.93M

Abivax SA Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 79.20
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABVX, the sentiment is Positive. The current price of 79.2 is above the 20-day moving average (MA) of 77.08, above the 50-day MA of 72.28, and above the 200-day MA of 27.55, indicating a bullish trend. The MACD of 2.53 indicates Positive momentum. The RSI at 58.07 is Neutral, neither overbought nor oversold. The STOCH value of 26.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ABVX.

Abivax SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GNFT	60 Neutral	$186.12M	-4.79	-51.06%	―	-45.41%	-273.69%
ABVX	54 Neutral	€6.16B	-28.33	―	―	―	18.52%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DBV	50 Neutral	€395.11M	-2.59	-152.03%	―	―	-20.97%
IPH	48 Neutral	$170.51M	-3.37	-271.32%	―	-75.86%	-30.54%
VLA	45 Neutral	€698.33M	-9.84	-38.01%	―	30.21%	-76.83%
IVA	39 Underperform	€443.16M	-0.81	―	―	-12.84%	-81.94%